• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实验性变应性鼻炎期间的血浆激肽释放酶:在激肽形成中的作用及对鼻分泌物中TAME酯酶活性的影响

Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions.

作者信息

Baumgarten C R, Nichols R C, Naclerio R M, Lichtenstein L M, Norman P S, Proud D

出版信息

J Immunol. 1986 Aug 1;137(3):977-82.

PMID:3522740
Abstract

We have shown recently that kinins are generated during experimentally induced allergic rhinitis in man, and have demonstrated that substrates for kinin-forming enzymes are provided during the allergic response by a transudation of kininogens from plasma into nasal secretions. In light of this increased vascular permeability during the allergic reaction, we have extended our studies on the mechanisms of kinin formation to examine the potential involvement of plasma kallikrein. Allergic individuals (n = 7) and nonallergic controls (n = 7) were challenged intranasally with an allergen, and nasal lavages, obtained before and after challenge, were assayed for immunoreactive human plasma kallikrein/prekallikrein (iHPK). Post-challenge iHPK values were significantly elevated (p less than 0.01) in the allergic group (353 +/- 394 ng/ml; x +/- SD) as compared to the nonallergics (19 +/- 22 ng/ml), and correlated with increases in kinins, histamine, and N-alpha-tosyl-L-arginine methyl esterase (TAME-esterase) activity and with the onset of clinical symptoms. Gel filtration studies revealed that plasma prekallikrein is activated during the allergic response and contributes to kinin formation prior to interaction with plasma protease inhibitors. We also show that the majority of the TAME-esterase activity detected in nasal secretions during the allergic response is due to activities consistent with a plasma kallikrein/alpha 2-macroglobulin complex and with mast cell tryptase.

摘要

我们最近已表明,在人体实验性变应性鼻炎期间会生成激肽,并且已证实,在变应性反应过程中,激肽原通过从血浆渗出至鼻分泌物中,为激肽形成酶提供了底物。鉴于变应性反应期间血管通透性增加,我们已将对激肽形成机制的研究扩展至检查血浆激肽释放酶的潜在参与情况。变应性个体(n = 7)和非变应性对照(n = 7)经鼻内给予变应原进行激发,对激发前后获得的鼻灌洗液检测免疫反应性人血浆激肽释放酶/前激肽释放酶(iHPK)。与非变应性个体(19 ± 22 ng/ml)相比,变应性组激发后iHPK值显著升高(p < 0.01)(353 ± 394 ng/ml;x ± SD),并且与激肽、组胺和N-α-甲苯磺酰-L-精氨酸甲酯酶(TAME-酯酶)活性的增加以及临床症状的出现相关。凝胶过滤研究显示,血浆前激肽释放酶在变应性反应期间被激活,并在与血浆蛋白酶抑制剂相互作用之前促进激肽形成。我们还表明,变应性反应期间在鼻分泌物中检测到的大部分TAME-酯酶活性归因于与血浆激肽释放酶/α2-巨球蛋白复合物以及肥大细胞类胰蛋白酶一致的活性。

相似文献

1
Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions.实验性变应性鼻炎期间的血浆激肽释放酶:在激肽形成中的作用及对鼻分泌物中TAME酯酶活性的影响
J Immunol. 1986 Aug 1;137(3):977-82.
2
Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis.在实验性诱发的变应性鼻炎期间,人鼻分泌物中腺激肽释放酶的浓度会升高。
J Immunol. 1986 Aug 15;137(4):1323-8.
3
Influx of kininogens into nasal secretions after antigen challenge of allergic individuals.变应性个体经抗原激发后激肽原流入鼻分泌物。
J Clin Invest. 1985 Jul;76(1):191-7. doi: 10.1172/JCI111945.
4
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen.在变应性个体的气道经变应原激发后,体内会生成激肽。
J Clin Invest. 1983 Nov;72(5):1678-85. doi: 10.1172/JCI111127.
5
Kininogens in nasal secretions after allergen challenge.变应原激发后鼻分泌物中的激肽原。
Adv Exp Med Biol. 1986;198 Pt B:189-92. doi: 10.1007/978-1-4757-0154-8_23.
6
Kinin metabolism in human nasal secretions during experimentally induced allergic rhinitis.实验性变应性鼻炎期间人鼻分泌物中的激肽代谢
J Immunol. 1987 Jan 15;138(2):428-34.
7
A study of the plasma kinin-generating system in children with the minimal lesion, idiopathic nephrotic syndrome.一项关于微小病变型特发性肾病综合征患儿血浆激肽生成系统的研究。
Pediatr Res. 1975 Sep;9(9):705-9. doi: 10.1203/00006450-197509000-00004.
8
Inflammatory mediators in late antigen-induced rhinitis.晚期抗原诱导性鼻炎中的炎症介质
N Engl J Med. 1985 Jul 11;313(2):65-70. doi: 10.1056/NEJM198507113130201.
9
Substance P is generated in vivo following nasal challenge of allergic individuals with bradykinin.在变应性个体经缓激肽进行鼻腔激发后,体内可产生P物质。
Clin Exp Allergy. 1997 Nov;27(11):1322-7.
10
Effect of intranasal capsaicin on symptoms and mediator release.
J Pharmacol Exp Ther. 1991 Dec;259(3):1323-7.

引用本文的文献

1
Nasal mucus proteome and its involvement in allergic rhinitis.鼻腔黏液蛋白质组及其在变应性鼻炎中的作用。
Expert Rev Proteomics. 2020 Mar;17(3):191-199. doi: 10.1080/14789450.2020.1748502. Epub 2020 Apr 8.
2
Active plasma kallikrein localizes to mast cells and regulates epithelial cell apoptosis, adipocyte differentiation, and stromal remodeling during mammary gland involution.活性血浆激肽释放酶定位于肥大细胞,并在乳腺退化过程中调节上皮细胞凋亡、脂肪细胞分化和基质重塑。
J Biol Chem. 2009 May 15;284(20):13792-13803. doi: 10.1074/jbc.M900508200. Epub 2009 Mar 18.
3
Bradykinin formation. Plasma and tissue pathways and cellular interactions.
缓激肽的形成。血浆和组织途径以及细胞相互作用。
Clin Rev Allergy Immunol. 1998 Winter;16(4):403-29. doi: 10.1007/BF02737659.
4
The kinin system in rhinitis and asthma.鼻炎和哮喘中的激肽系统。
Clin Rev Allergy Immunol. 1998 Winter;16(4):351-64. doi: 10.1007/BF02737656.
5
Nonallergic rhinitis. Pathophysiology and models for study.非变应性鼻炎。病理生理学与研究模型。
Eur Arch Otorhinolaryngol. 1995;252 Suppl 1:S27-32. doi: 10.1007/BF02484431.
6
Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation.人类嗜酸性粒细胞颗粒主要碱性蛋白和合成聚阳离子在体内诱导气道高反应性,这依赖于缓激肽的生成。
J Clin Invest. 1995 Apr;95(4):1735-40. doi: 10.1172/JCI117850.
7
Reversibility and reproducibility of histamine induced plasma leakage in nasal airways.组胺诱导的鼻气道血浆渗漏的可逆性和可重复性。
Thorax. 1989 Jan;44(1):13-8. doi: 10.1136/thx.44.1.13.
8
A competitive kinin receptor antagonist, [DArg0, Hyp3, DPhe7]-bradykinin, does not affect the response to nasal provocation with bradykinin.一种竞争性激肽受体拮抗剂,[D-精氨酸0,组氨酸3,D-苯丙氨酸7]-缓激肽,不影响对缓激肽鼻腔激发试验的反应。
Br J Clin Pharmacol. 1991 Mar;31(3):287-94. doi: 10.1111/j.1365-2125.1991.tb05532.x.